Schering May Cough Up Hefty Payment to FDA
Schering-Plough (SGP ) says it may have to pay up to $500 million to resolve manufacturing issues with the U.S. Food and Drug Administration. The company received FDA approval for its Clarinex antihistamine. Schering sees fourth-quarter EPS from operations about 7% below one year ago, and 2002 EPS growth in the low double-digits. Goldman cut its estimates on Schering.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.